Skip to main content

Author: Bill Snyder

Reduced kidney function may cause cardiovascular disease: study

Dec. 15, 2022—An international team of investigators has found that mild to moderate reduction in kidney function may cause cardiovascular disease, even in people without symptoms of heart disease or diabetes.

Read more


Nephrology society lauds Bock’s research on kidney development

Dec. 15, 2022—Vanderbilt's Fabian Bock, MD, PhD, won two awards at the Basic Research Forum for Emerging Kidney Scientists, presented virtually by the American Society of Nephrology and American Physiological Society.

Read more


VUMC well represented at Association of American Medical Colleges annual meeting

Dec. 14, 2022—Several Vanderbilt University Medical Center faculty were featured in the annual meeting of the Association of American Medical Colleges in Nashville.

Read more


Grants spur efforts to create molecular ‘atlases’ of organs

Nov. 17, 2022—Vanderbilt researchers have received three grants totaling $13.6 million from the National Institutes of Health to develop molecular “atlases” of the brain, kidney, eye and other tissues.

Read more


Several from VUMC among most highly cited researchers

Nov. 17, 2022—Nine current faculty members of the Vanderbilt University School of Medicine have made this year’s list of scientists whose papers have been cited most frequently by other researchers.

Read more


Department of Psychiatry and Behavioral Sciences celebrates 75 years

Nov. 14, 2022—The Department of Psychiatry and Behavioral Sciences celebrated its 75th anniversary on Nov. 11 with an afternoon program that highlighted its contributions to professional education, research, and clinical care.

Read more


Gastric Cancer Foundation funds Eunyoung Choi research

Nov. 10, 2022—The Gastric Cancer Foundation has awarded a one-year $100,000 research grant to Eunyoung Choi, PhD, to support her efforts to find a way to disrupt the transformation of dysplastic stem cells into stomach cancer.

Read more


AstraZeneca VP to discuss COVID-19 collaboration with VUMC Nov. 17

Nov. 10, 2022—On Thursday, Nov. 17, Mark Esser, PhD, vice president, Early Vaccines and Immune Therapies R&D at AstraZeneca, will discuss his company’s collaboration with Vanderbilt University Medical Center that led to development of the Evusheld antibody combo to prevent COVID-19 in high-risk individuals.

Read more


Hawiger still blazing a trail in inflammation research

Nov. 10, 2022—Vanderbilt research describes a new investigational peptide drug that can penetrate immune and nonimmune cells, and block inflammatory signaling in a preclinical model of atopic dermatitis — eczema.

Read more


Study defines role of steroids in congenital heart disease surgery

Nov. 10, 2022—Steroids are commonly given to infants during open-heart surgery to reduce inflammation, but whether the drugs significantly improve patient outcomes has not been settled — until now.

Read more


Study finds Moderna’s COVID-19 vaccine safe and effective for young children

Nov. 4, 2022—A Vanderbilt study finds that Moderna’s COVID-19 vaccine is safe and effective in children 6 months to 5 years of age.

Read more


Event to spotlight VUMC’s COVID-19 research efforts

Nov. 3, 2022—The public is invited to listen in as scientists on the forefront of COVID-19 research at Vanderbilt University Medical Center share their personal stories on Wednesday afternoon, Nov. 16, in 214 Light Hall.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more